ReviewNeuroscience applied2025
The gut microbiota's role in bulimia nervosa and binge eating disorder: etiological insights and therapeutic implications from a scoping review.
Review in Neuroscience applied, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review synthesizes emerging evidence on the relationship between gut microbiota and eating disorders (EDs), particularly bulimia nervosa (BN) and binge eating disorder (BED). An electronic search was conducted in the PubMed/MEDLINE and Web of Science databases, spanning from their inception until December 2023. From an initial pool of 166 records, 14 articles were included and qualitatively synthesized. Two overarching themes emerged. The first focuses on etiological hypotheses, pointing to autoimmunity and psychoneuroendocrinoimmunological mechanisms as potential mediators in the association between ED pathophysiology and the gut microbiota. Significant findings include the identification of elevated levels of bacterial caseinolytic protease B protein in patients, correlating with symptom severity and specific autoantibodies. Furthermore, studies indicate that gut microbiota proteins might trigger autoantibody production. Distinct microbial profiles are associated with different ED subtypes and behaviors. The second theme examines the clinical implications of this link. Human trials demonstrate the potential of probiotic interventions in improving eating-related clinical outcomes post-bariatric surgery. Murine models also demonstrate the role of gut microbiota in controlling compulsive overeating, with probiotic interventions proving effective in reducing binge eating and anxiety-like behaviors. In conclusion, this review summarizes current research and highlights the interactions among the gut microbiota, immune system, and hormonal regulation in the development and progression of BN and BED. It also highlights the potential for ongoing interdisciplinary research to identify possible underlying mechanisms and reliable biomarkers, with the ultimate goal of developing targeted therapeutic interventions for BN and BED.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.